| 摘要 |
The invention relates to an anti fibrinolytic composition comprising at least one tPA 481 mutant that carries at least one point mutation substituting Ser to Ala on tPA, said mutant inhibits the fibrinolytic activity of at least one of tPA and uPA and therefore may be used for treating disorders associated with fibrinolytic processes, specifically, coagulopathies, thrombocytopenia and bleeding. The invention further provides methods and uses of the mutants of the invention. |
